Cross Track Symposium 2 - Viral Hepatitis in Correctional Settings
| Tuesday, August 14, 2018 |
| 11:30 AM - 1:00 PM |
| Hall M (Ground Floor) |
Details
Learning Objectives - Attendees will become familiarised with HCV transmission and care delivery challenges, including facilitators and barriers to HCV treatment uptake within the prison setting (LL - social), novel HCV models of care (ET – clinical; LM - clinical), and HCV transmission and risk behaviours (BH – epi). They will also become familiarised with HBV epidemiology, prevention and clinical care within prisons in the NT (where HBV prevalence is highest among the prisoner population) (CM – HBV)
Speaker
Attendee159
Attendee757
Attendee517
Attendee673
Attendee513
Attendee753
Facilitator: Andrew Lloyd. Panellist: Mark Stoove, Carla Treloar, Edmund Tse, Behzad Hajari, Jane Davies, Anne Craigie, Michael Ninburg, Shannon Wright, Michael Levy
12:20 PM - 1:00 PMBrief Overview
• Do prison settings provide opportunities or challenges for HCV elimination in the community?
• Is any of existing HCV models of care effective and feasible enough to be utilised in the national level?
• What is the role of HCV prevention strategies in the Australian prisons in DAA era when there is unrestricted access to an effective cure? (role of harm reduction and reinfection)
What are the existing challenges in delivering HBV vaccination and treatment in the prison settings?
• Is any of existing HCV models of care effective and feasible enough to be utilised in the national level?
• What is the role of HCV prevention strategies in the Australian prisons in DAA era when there is unrestricted access to an effective cure? (role of harm reduction and reinfection)
What are the existing challenges in delivering HBV vaccination and treatment in the prison settings?
Biography
Chair
Attendee322
Attendee485
